drugset / Trial / NCT01793090

EPI-743 in Cobalamin C Defect: Effects on Visual and Neurological Impairment

NCT01793090 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of the research is to investigate the safety and efficacy of EPI-743 treatment in patients with Cbl-C defect and related visual and neurological impairment. Primary Endpoints will be the improvement in visual function as assessed by visual acuity and eye-hand coordination and manual dexterity. Secondary Endpoints will be the improvement in neurologic function, evaluated by a battery of age-appropriated psychophysical tests, and/or in objective electrophysiological tests such as Visual Evoked potentials (VEP) and Electroretinogram (ERG) and/or the change in serum markers of redox state.

Timeline

Start
2013-01
Primary completion
2013-07
Completion
2017-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Vatiquinone Small molecule 100 mg Oral
Comparator Vatiquinone Small molecule 200 mg Oral